Work

Clinical Outcomes of Dacarbazine After Failure of Immune Checkpoint Inhibitors: A Case Study of 15 Japanese Patients With Malignant Melanoma

Year: 2026

Type: article

Abstract: Immune checkpoint inhibitors (ICIs) have become the standard systemic treatment for advanced malignant melanoma (MM); however, > 50% of Asian patients do not respond to ICIs [1].Dacarbazine, the previous standard treatment, remains occasionally used.However, there are few reports on the efficacy of dacarbazine after ICI treatment in Asian patients.Here, we report the clinical outcome of dacarbazine after ICI failure in Japanese patients with MM at our institution.

Source: The Journal of Dermatology

DOI: 10.1111/1346-8138.70181

Authors: Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara

Institutions: Shizuoka Cancer Center, Nagoya University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,630